Press releases
2019
16 December, 2019
Global phase III study POLAR-A fully recruited
10 December, 2019
PLEDPHARMA’S ASIAN PARTNER SOLASIA ENTERS AGREEMENT WITH JAPANESE MARUHO FOR COMMERCIALIZATION OF PLEDOX®
29 October, 2019
PledPharma publishes prospectus in connection with the list change to Nasdaq Stockholm’s main market
23 October, 2019
Interim report January-September 2019
16 October, 2019
PledPharma approved for listing on Nasdaq Stockholm
21 August, 2019
Half-Year report January-June 2019
15 July, 2019
The Lancet EBioMedicine publishes Aladote® study results
11 July, 2019
Aladote® – regulatory interactions
21 May, 2019
PledPharma completes a Directed New Share Issue of 4,866,665 shares, raising proceeds of SEK 91 million
6 May, 2019
Interim report January-March 2019
12 April, 2019
PledPharma's drug candidate Aladote® is highlighted at one of the largest liver conferences globally
8 April, 2019
NOTICE OF ANNUAL GENERAL MEETING OF PLEDPHARMA AB
8 April, 2019
PledPharma’s 2018 annual report published
26 March, 2019
PledPharma will be presenting company’s drug development programs at today’s CMD in Stockholm
14 March, 2019
PledPharma Capital Markets Day, March 26
21 February, 2019
Year-end Report January-December 2018
5 February, 2019
PledPharma Capital Markets Day
Calendar and upcoming reports
April 15, 2024
Annual Report 2023
May 3, 2024
Interim Report Q1 2024 (7:00am CEST)
